Grant: Master's Award: Canada Graduate Scholarships
McMaster University
$17,500.00
Elucidating the Mechanisms of Selective Drugs for Human Cancer Stem Cells
EF 2023-24
Résumé
Lay Title: Understanding Novel Drugs for Human Cancer Treatment
Cancer is the leading cause of death in Canada, affecting 2 out of 5 Canadians. Among the various types of cancer, one particularly challenging and aggressive form is Acute Myeloid Leukemia (AML). Traditional AML therapy, involving non-specific chemotherapy, can lead to initial remission, however, relapse is common, resulting in a less than 30% survival of patients after 5 years. Disease relapse is thought to be coming from the survival of a unique and very rare group of cells within a tumor, known as cancer stem cells (CSCs). These CSCs are different from the rest of the tumor and have the remarkable ability to survive even after chemotherapy. This resilience allows the tumor to regrow, ultimately leading to relapse disease in patients that no longer respond to standard therapies. To prevent relapse of disease, new drugs are required, and we must modify existing drug development approaches to discover therapies that target rare CSCs.
We aim to understand the genetic variances between CSCs and healthy stem cells, with the goal of specifically targeting and eradicating CSCs while leaving healthy stem cells unharmed. Over the past decade, our research has created a method to identify novel chemical compounds that can kill CSCs but not healthy cells. We have identified 2 such molecules over 10 years of this week, and now want to know the mechanism of how they kill CSCs but leave normal cells alone. By knowing how these molecules work, we will position them for the first steps in approval towards cancer drug candidates in clinical trials as alternatives when traditional chemotherapy doesn’t work.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
506280
Name
Statchuk Meghan
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Elucidating the Mechanisms of Selective Drugs for Human Cancer Stem Cells
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biological Assays; Cancer Stem Cell (Csc) Biology; Cancer/Acute Myeloid Leukemia; Determination Of Mechanism Of Action; Drug Development/Phenotypic Drug Discovery; Multidisciplinary Research; Novel Cancer Therapeutics/Csc-Targeted Therapeutics; Pharmacokinetic Assesment; Proprietary Csc Model; Rna Sequencing
Abstract
Lay Title: Understanding Novel Drugs for Human Cancer Treatment
Cancer is the leading cause of death in Canada, affecting 2 out of 5 Canadians. Among the various types of cancer, one particularly challenging and aggressive form is Acute Myeloid Leukemia (AML). Traditional AML therapy, involving non-specific chemotherapy, can lead to initial remission, however, relapse is common, resulting in a less than 30% survival of patients after 5 years. Disease relapse is thought to be coming from the survival of a unique and very rare group of cells within a tumor, known as cancer stem cells (CSCs). These CSCs are different from the rest of the tumor and have the remarkable ability to survive even after chemotherapy. This resilience allows the tumor to regrow, ultimately leading to relapse disease in patients that no longer respond to standard therapies. To prevent relapse of disease, new drugs are required, and we must modify existing drug development approaches to discover therapies that target rare CSCs.
We aim to understand the genetic variances between CSCs and healthy stem cells, with the goal of specifically targeting and eradicating CSCs while leaving healthy stem cells unharmed. Over the past decade, our research has created a method to identify novel chemical compounds that can kill CSCs but not healthy cells. We have identified 2 such molecules over 10 years of this week, and now want to know the mechanism of how they kill CSCs but leave normal cells alone. By knowing how these molecules work, we will position them for the first steps in approval towards cancer drug candidates in clinical trials as alternatives when traditional chemotherapy doesn’t work.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Statchuk, Meghan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~